The use of accelerator mass spectrometry to obtain early human ADME/PK data.
about
Opportunities in low-level radiocarbon microtracing: applications and new technologyAccelerator mass spectrometry-enabled studies: current status and future prospects.Alternative (non-animal) methods for cosmetics testing: current status and future prospects-2010.Yeast dynamic metabolic flux measurement in nutrient-rich media by HPLC and accelerator mass spectrometry.The use of isotopes in the determination of absolute bioavailability of drugs in humans.Quantifying Carbon-14 for Biology Using Cavity Ring-Down Spectroscopy.Challenges and solutions to metabolites in safety testing: impact of the International Conference on Harmonization M3(R2) guidance.Early human ADME using microdoses and microtracers: bioanalytical considerations.From definition to implementation: a cross-industry perspective of past, current and future MIST strategies.LC-MS/MS bioanalytical challenge: ultra-high sensitivity assays.Microdosing studies using accelerated mass spectrometry as exploratory investigational new drug trials.Oral bioavailability: issues and solutions via nanoformulations.A combined accelerator mass spectrometry-positron emission tomography human microdose study with 14C- and 11C-labelled verapamil.Sensitivity and proportionality assessment of metabolites from microdose to high dose in rats using LC-MS/MS.High-sensitive LC-MS/MS method for the simultaneous determination of mirodenafil and its major metabolite, SK-3541, in human plasma: application to microdose clinical trials of mirodenafil.Biomedical accelerator mass spectrometry: recent applications in metabolism and pharmacokineticsTracking Tumor Colonization in Xenograft Mouse Models Using Accelerator Mass Spectrometry
P2860
Q28817904-6152F2AF-1EFC-4A2C-A07D-1D0F26DF7E0DQ33819361-010EC737-25C5-42A7-AC05-FE9419EA4953Q34181630-005E1BF9-FB56-4CFC-B94D-C5C877D44F71Q34372537-68C71F38-C248-4686-BEA4-0CAA9938FAF7Q34550493-377609F3-0B2D-402E-A48F-84DA88D8FDF4Q37600860-32D87F72-E4A3-4114-B74E-73C52FBCA10CQ37808484-64B54A10-C153-4765-A717-7DA13073F6F2Q37810234-DD2B7131-E3E0-44BA-9B87-F3964DB900D5Q37859007-C3B2A783-B2CB-48A3-9819-26A7F44AEDBDQ37923935-09577DA3-B7AF-4A7F-89B2-4776C8103285Q37964571-9551FEB4-7CCE-4003-88DC-260209D2A9D2Q38349734-EDA5691C-8FE2-4AFE-81A8-05874945D051Q42585832-0D96529D-AD25-42B9-971C-61FBDAA09322Q42807076-9A70B532-5520-418C-9448-623E8207FCD0Q46425275-F328842B-6A91-4AE6-A02E-2163BD68AC14Q56430923-5CEB8F2D-4D7B-4A99-81B4-DB4A27DA0CC7Q57292362-9D3CA2DA-79E9-4C94-9984-76BA950DA9C5
P2860
The use of accelerator mass spectrometry to obtain early human ADME/PK data.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
The use of accelerator mass spectrometry to obtain early human ADME/PK data.
@ast
The use of accelerator mass spectrometry to obtain early human ADME/PK data.
@en
type
label
The use of accelerator mass spectrometry to obtain early human ADME/PK data.
@ast
The use of accelerator mass spectrometry to obtain early human ADME/PK data.
@en
prefLabel
The use of accelerator mass spectrometry to obtain early human ADME/PK data.
@ast
The use of accelerator mass spectrometry to obtain early human ADME/PK data.
@en
P2860
P356
P1476
The use of accelerator mass spectrometry to obtain early human ADME/PK data.
@en
P2093
Graham Lappin
R Colin Garner
P2860
P356
10.1517/17425255.1.1.23
P407
P577
2005-06-01T00:00:00Z